Figure 8
ATL146e targets A2ARs on iNKT cells to decrease pulmonary inflammation. NY1DD x Rag1−/− mice were pretreated with ATL146e (10 ng/kg/minute, 3 days). Two days later, 106 NKT cells pretreated in vitro with vehicle or 200nM concentrations of the A2AR alkylating agent, FSPTP, were adoptively transferred. Pulmonary parameters were analyzed on day 3 by 1-way ANOVA with Neuman-Keuls posttesting. P < .05: + vs B6; * vs SCD; ** vs SCD - Rag1; # vs SCD-Rag1 + NKT cells; *** vs ATL146e pretreated SCD x Rag1 + NKT cells. B6 = C57BL6; SCD = NY1DD; ViNKT = vehicle-treated iNKT cells; FiNKT = FSPTP-treated iNKT cells.
